Nasal polyposis and cystic fibrosis (CF): Review of the literature

Rhinology

Volumn 49, Issue 3, 2011, Pages

  Feuillet Fieux, Marie Noelle ^a   Lenoir, Gerard ^a   Sermet, Isabelle ^a   Elie, Caroline ^a,b   Djadi Prat, Juliette ^a   Ferrec, Magali ^a   Magen, Maryse ^a   Simon, Marie ^a   Couloigner, Vincent ^a   Manach, Yves ^a   Lacour, Bernard ^a,b   Bonnefont, Jean Paul ^a,b  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

CFTR; CFTR mutations; Cystic fibrosis; Genotype phenotype relationship; Nasal polyposis

Indexed keywords

TRANSMEMBRANE CONDUCTANCE REGULATOR;

ADULT; CASE REPORT; CYSTIC FIBROSIS; GENETICS; HOSPITALIZATION; HUMAN; MALE; NOSE POLYP; NUCLEOTIDE SEQUENCE; REVIEW; RISK FACTOR;

ADULT; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DNA MUTATIONAL ANALYSIS; HUMANS; MALE; NASAL POLYPS; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 80051779549     PISSN: 03000729     EISSN: None     Source Type: Journal    
DOI: 10.4193/Rhino10.225     Document Type: Review

References (48)

1. Kingdom TT, Lee KC, Fitzsimmons SC, et al. Clinical characteristics and genotype analysis of patients with cystic fibrosis and nasal polyposis requiring surgery. Arch Otolaryngol Head Neck Surg. 1996; 122: 1209-1213.
2. De Gaudemar I, Contencin P, Vanden Abbeele T, et al. Is nasal polyposis in cystic fibrosis a direct manifestation of genetic mutation or complication of chronic infection? Rhinology. 1996; 34: 194-197.
3. Hadfield PJ, Rowe-Jones JM, Mackay IS. The prevalence of nasal polyps in adults with cystic fibrosis. Clin Otolaryngol. 2000; 25: 19-22.
4. Henriksson G, Westrin KM, Karpati F, et al. Nasal polyps in cystic fibrosis: clinical endoscopic study with nasal lavage fluid analysis. Chest. 2002; 121: 40-47.
5. Cimmino M, Cavaliere M, Nardone M, et al. Clinical characteristics and genotype analysis of patients with cystic fibrosis and nasal polyposis. Clin Otolaryngol. 2003; 28: 125-132.
6. Slieker MG, Schilder AG, Uiterwaal CS, Vander En CK. Who should visit the otorhinolaryngologist? Arch Otolaryngol Head Neck Surg. 2002; 128: 1245-1248.
7. Kerrebijn JD, Poublon RM, Overbeek SE. Nasal and paranasal disease in adult cystic fibrosis patients. Eur Respir J. 1992; 5: 1239-1242.
8. Triglia JM, Nicollas R. Nasal and sinus polyposis in children. Laryngoscope. 1997; 107: 963-966.
9. Yung MW, Gould J, Upton GJ. Nasal polyposis in children with cystic fibrosis: a long-term follow-up study. Ann Otol Rhinol Laryngol. 2002; 111: 1081-1086.
10. Audrezet MP, Mercier B, Guillermit H, et al. Identification of 12 novel mutations in the CFTR gene. Hum Mol Genet. 1993; 2: 51-54.
11. Feuillet-Fieux MN, Ferrec M, Gigarel N, et al. Novel CFTR mutations in black cystic fibrosis patients. Clin Genet. 2004; 65: 284-287.
12. Amaral MD, Pacheco P, Beck S, et al. Cystic fibrosis patients with the 3272-26A>G splicing mutation have milder disease than F508del homozygotes: a large European study. J Med Genet. 2001; 38: 777-783.
13. Jorissen MB, De Boeck K, Cuppens H. Genotype-phenotype correlations for the paranasal sinuses in cystic fibrosis. Am J Respir Crit Care Med. 1999: 159: 1412-1416.
14. Weber SA, Ferrari GF. Incidence and evolution of nasal polyps in children and adolescents with cystic fibrosis. Rev Bras Otorhinolaryngol. 2008; 74: 16-20.
15. Shwachman H, Kulczycki LL. Longterm study of one hundred and five patients with cystic fibrosis: studies made over five to fourteen year period. Am J Dis Child. 1958; 96: 6-15.
16. Mackay IS and Lund VJ. Imaging and staging. In: Polyps: an inflammatory disease and treatment. 1997; 137 Munskgaard, Copenhagen.
17. Pawankar R, Nasal polyposis: an update. Curr Opin Allergy Clin Immunol. 2003: 3: 1-6.
18. Grigoreas C, Vourdas D, Petala K, et al. Nasal polyps in patients with rhinitis and asthma. Allergy Asthma Proc. 2002; 23: 169-174.
19. Bateman ND, Fahy C, Woolford TJ. Nasal polyps: still more questions than answers. J Laryngol Otol. 2003; 117: 1-9.
20. Pinto JM, Hayes MG, Schneider D, Naclerio RM, Ober C. A genomewide screen for chronic rhinosinusitis genes identifies a locus on chromosome 7q. Laryngoscope. 2008; 118: 2067-2072.
21. Babinski D, Trawinska-Bartnicka M. Rhinosinusitis in cystic fibrosis: not a simple story. Int J Pediatr Otorhinolaryngol. 2008; 72: 619-624.
22. Stern RC, Boat TF, Wood RE, et al. Treatment and prognosis of nasal polyps in cystic fibrosis. Am J Dis Child. 1982; 136: 1067-1070.
23. Schmitt EJ, Neaville W, Pongdee T. Prevalence of cystic fibrosis in children who present with nasal polyp sis. J Allergy Clin Immunol. 2005; 115 S1:516.
24. Varon R, Magdorf K, Staab D, et al. Recurrent nasal polyps as a monosymptomatic form of cystic fibrosis associated with a novel in-frame deletion (519 del18) in the CFTR gene. Hum Mol Genet. 1995; 8: 1463-1464.
25. Fidalgo Alvarez I, Lopez Pacios D, et al. Chronic sinusitis and nasal polyps as the initial manifestation of cystic fibrosis. Acta Otorinolaringol Esp. 1993; 44: 457-459.
26. Dequeker E, Stuhrmann M, Morris MA, et al. Best practice guidelines for molecular genetic diagnosis of cystic fibrosis and CFTR-related disorders--updated European recommendations. Eur J Hum Genet. 2009; 17: 51-65.
27. Kerem BS, Zielenski J, Markiewicz D, et al. Identification of mutations in region corresponding to the putative nucleotide (ATP)-binding folds of the cystic fibrosis gene. Proc Natl Acad Sci USA. 1990; 87: 8447-8451.
28. Kristidis P, Bozon D, Corey M, et al. Genetic determination of exocrine pancreatic function in cystic fibrosis. Am J Hum Genet. 1992; 50: 1178-84.
29. Fanen P, Ghanem M, Vidaud M, et al. Molecular characterisation of cystic fibrosis: 16 novel mutations identified by analysis of whole Cystic Fibrosis Regulator (CFTR) coding regions and splice site junction. Genomics. 1992; 132: 770-776.
30. Costes B, Girodon E, Ghanem N, et al. Frequent occurence of the CFTR intron 8 (TG)n5T allele in men with congenital bilateral absence of the vas deferens. Eur J Hum Genet. 1995; 3: 285-293.
31. Feldmann D, Balloul H, Magnier C, et al. Cystic Fibrosis Mutation Data Base (http://www.genet.sickkids.on.ca/) October 4, 1995.
32. Ingster O, Norez C, About F, et al. Etudes moléculaires, cellu-laires et fonctionnelles de 6 mutations rares du gène CFTR. Med Sci. 2006; 2/22: 149, abstract P397.
33. Ferec C, Novelli G, Verlingue C et al. Identification of six novel CFTR mutations in a sample of Italian cystic fibrosis patients. Mol Cell Probes 1995; 9: 135-137.
34. Chu CS, Trapnell BC, Curristin S, et al. Genetic basis of variable exon 9 skipping in cystic fibrosis transmembrane conductance regulator mRNA. Nature Genet. 1993; 3: 151-156.
35. Chu CS, Trapnell BC, Curristin S, et al. Extensive posttranscrip-tional deletion of the coding sequences for part of nucleotide-binding fold 1 in respiratory epithelial mRNA transcripts of the cystic fibrosis transmembrane conductance regulator gene is not associated with the clinical manifestations of cystic fibrosis. J Clin Invest. 1992; 90: 785-790.
36. Cuppens H, Lin W, Costes B et al. Polyvariant mutant cystic fibrosis transmembrane conductance regulator genes. J Clin Invest. 1998; 101: 487-496.
37. Noone PG, Pue CA, Zhou Z, et al. Lung disease associated with the IVS8-5T allele of the CFTR gene. Am J Respir Crit Care Med. 2000; 162: 1919-1924.
38. Friedman KJ, Heim RA, Knowles MR, et al. Rapid characterisation of the variable length polythymidine tract in the cystic fibrosis (CFTR) gene: association of the 5T allele with selected CFTR mutations and its incidence in atypical sinopulmonary disease. Hum Mut. 1997; 9: 108-115.
39. Chillon M, Casals T, Mercier B, et al. Mutations in the cystic fibrosis gene in patients with congenital absence of the vas defer-ens. N Engl J Med. 1995; 332: 1475-1480.
40. Pignatti PF, Bombieri C, Benetazzo M, et al. CFTR gene variant IVS8-5T in disseminated bronchiectasis. Am J Hum Genet. 1996; 58: 889-892.
41. Bishop MD, Freedman SD, Zielenski J, et al. The cystic fibrosis transmembrane conductance regulator gene and ion channel function in patients with idiopathic pancreatitis. Hum Genet. 2005; 118: 372-381.
42. Kerem E, Rave-Harel N, Augarten A, et al. Clinical presentation of patients carrying the 5 thymidine tract in intron 8. From healthy individuals to typical CF. Pediatr Pulmonol. 1995; 12: 203.
43. Groman JD, Hefferon TW, Casals T, et al. Variation in a repeat sequence determines whether a common variant of the cystic fibrosis transmembrane conductance regulator gene is pathogenic or benign. Am J Hum Genet. 2004; 74: 176-179.
44. Niksic M, Romano M, Buratti E, et al. Functional analysis of cis-acting elements regulating the alternative splicing of human CFTR exon 9. Hum Mol Genet. 1999; 8: 2339-2349.
45. Kostuch M, Klatka J, Semczuk A, et al. Analysis of most common CFTR mutations in patients affected by nasal polyps. Eur Arch Oto-Rhino-Laryngol. Head Neck. 2005; 262: 982-986.
46. Bürger J, Macek M, Stuhrmann M, et al. Genetic influences in the formation of nasal polyps. Lancet. 1991; 337: 974.
47. Irving RM, McMahon R, Clark R, et al. Cystic fibrosis trans-membrane conductance regulator gene mutations in severe nasal polyposis. Clin Otolaryngol. 1997: 22: 519-521.
48. Wang XJ, Moylan B, Leopold DA, et al. Mutation in the gene responsible for cystic fibrosis and predisposition to chronic rhinos-inusitis in the general population. JAMA. 2000; 284: 1814-1819.